Cogent Biosciences (COGT) EBIT (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly EBIT of -$103.6 million for Q1 2026, down 38.27% year-over-year from -$167.8 million in Q1 2025, and down 4.13% quarter-over-quarter from -$99.5 million in Q4 2025.
Cogent Biosciences (COGT) EBIT (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported EBIT for 10 consecutive years, with -$103.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 38.27% year-over-year to -$103.6 million; the TTM figure through Mar 2026 stood at -$362.0 million (down 25.5% YoY), while the FY2025 annual figure was -$333.4 million, down 20.81% from the prior year.
- EBIT declined to -$103.6 million in Q1 2026 per COGT's latest filing, from -$99.5 million in the prior quarter.
- Across five years, EBIT topped out at -$31.4 million in Q1 2022 and bottomed at -$103.6 million in Q1 2026.
- Historically, EBIT has averaged -$62.9 million across 5 years, with a median of -$62.4 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT tumbled 145.45% — and 2025, when it slipped 10.53%.
- Cogent Biosciences' EBIT stood at -$43.7 million in 2022, then tumbled by 33.11% to -$58.2 million in 2023, then decreased by 26.63% to -$73.7 million in 2024, then sank by 34.94% to -$99.5 million in 2025, then dropped by 4.13% to -$103.6 million in 2026.
- Business Quant data shows COGT's EBIT at -$103.6 million in Q1 2026, -$99.5 million in Q4 2025, and -$83.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | -102.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -102.64 Mn |
| Mar 31, 2026 | -103.61 Mn |
| Dec 31, 2025 | -99.49 Mn |
| Sep 30, 2025 | -83.36 Mn |
| Jun 30, 2025 | -75.58 Mn |
| Mar 31, 2025 | -74.93 Mn |
| Dec 31, 2024 | -73.73 Mn |
| Sep 30, 2024 | -75.41 Mn |
| Jun 30, 2024 | -64.39 Mn |
| Mar 31, 2024 | -62.40 Mn |
| Dec 31, 2023 | -58.23 Mn |
| Sep 30, 2023 | -59.58 Mn |
| Jun 30, 2023 | -47.09 Mn |
| Mar 31, 2023 | -43.24 Mn |
| Dec 31, 2022 | -43.75 Mn |
| Sep 30, 2022 | -36.82 Mn |
| Jun 30, 2022 | -35.86 Mn |
| Mar 31, 2022 | -31.42 Mn |
| Dec 31, 2021 | -25.64 Mn |
| Sep 30, 2021 | -19.82 Mn |